Pfizer (PFE) — Company Research
Last Updated: 31 May 2026
Pfizer Inc. (NYSE: PFE) is one of the world's largest biopharmaceutical companies, with a portfolio spanning oncology, vaccines, internal medicine, anti-infectives and rare disease. After the extraordinary rise and fall of its COVID-19 franchise, Pfizer is now a story of pipeline execution and capital allocation: defending the base business against a looming patent cliff while investing heavily in oncology and a newly acquired obesity platform. This report reviews the company's full-year 2025 results and first-quarter 2026 update using only company filings and press releases.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker | NYSE: PFE |
| Sector / Industry | Healthcare — Pharmaceuticals |
| Headquarters | New York City, USA (The Spiral, Manhattan) |
| Founded | 1849 |
| Employees | Approximately 81,000 |
| CEO / Leadership | Dr Albert Bourla (Chairman & Chief Executive Officer) |
| Market cap | ~$149 billion (late May 2026) |
| FY2025 revenue | $62.58 billion |
| FY2025 net income (GAAP) | $7.77 billion |
| FY2025 GAAP diluted EPS | $1.36 |
| FY2025 adjusted diluted EPS | $3.22 |
| Dividend (annualised) | $1.72 per share ($0.43 quarterly); ~6.6% yield |
| 52-week range | $23.06 – $28.75 |
2. Bull and Bear Case
Bull Case
- Deep value and high yield: At roughly 9x forward adjusted earnings and a ~6.6% dividend yield, expectations are low and the income is substantial.
- Oncology engine: The Seagen acquisition and products such as Padcev (up ~39% operationally in Q1 2026), Xtandi and Lorbrena give Pfizer a leading antibody-drug-conjugate and solid-tumour franchise.
- Obesity optionality: The ~$10bn Metsera acquisition adds ultra-long-acting incretin assets, with around ten pivotal obesity trials planned, opening a large new market.
- Cost discipline and cash: A multi-billion-dollar cost-realignment programme and ~$9.1bn of 2025 free cash flow support the dividend and reinvestment.
- Reaffirmed guidance: Management reaffirmed FY2026 revenue of $59.5–62.5bn and adjusted EPS of $2.80–3.00 after a Q1 beat.
Bear Case
- Patent cliff: By 2028 Pfizer expects to lose exclusivity on Eliquis, Ibrance, Xtandi and Prevnar, with an estimated $17–18bn of annual revenue at risk.
- IRA price pressure: A Medicare maximum fair price for Eliquis took effect in January 2026, eroding net revenue ahead of generic entry.
- Pipeline dependence: The thesis leans on R&D and obesity assets delivering; the oral GLP-1 danuglipron was discontinued in 2025, a reminder of clinical risk.
- Dilutive M&A: The Metsera deal is expected to be dilutive through 2030, and large acquisitions carry integration risk.
- COVID roll-off and FX: Comirnaty and Paxlovid revenues remain volatile and a drag on year-on-year comparisons.
3. Business Segments
Pfizer reports as a single biopharmaceutical business but manages it through three commercial units. Shares below are approximate groupings of FY2025 revenue; exact product-level detail is in the company's 10-K. Geographically, the United States generated $37.1bn (about 59%) and international markets $25.5bn (about 41%) of 2025 revenue.
| Segment | % of revenue | What it is |
|---|---|---|
| Primary Care | ~48% (approx.) | Vaccines and broadly prescribed medicines — Prevnar, Abrysvo, Comirnaty, Paxlovid, the Eliquis cardiovascular alliance and Nurtec migraine. |
| Specialty Care | ~26% (approx.) | Inflammation & immunology, rare disease and the Vyndaqel cardiomyopathy family. |
| Oncology | ~26% (approx.) | Solid-tumour and haematology portfolio including Padcev, Xtandi, Lorbrena, Ibrance and Seagen antibody-drug conjugates. |
4. Business Model and Moat
How it makes money. Pfizer discovers, develops, manufactures and sells patent-protected medicines and vaccines worldwide. Patents grant temporary exclusivity that supports premium pricing and high gross margins (cost of sales was about 26% of 2025 revenue); profits fund the next generation of R&D, which absorbed $10.4bn in 2025.
Why the moat exists. The combination of intellectual property, the cost and difficulty of clinical development, global regulatory approvals, manufacturing scale and entrenched physician relationships creates high barriers. Pfizer's vaccine platforms and its growing oncology ADC franchise are particularly defensible.
What management is prioritising. CEO Albert Bourla has pivoted the company beyond COVID toward oncology and obesity, pairing internal R&D with acquisitions (Seagen, Metsera) and roughly 20 planned pivotal trial starts in 2026 to rebuild growth ahead of the patent cliff.
5. Financial Health
Full-year figures are from Pfizer's audited results and quarterly press releases. Revenue is shown in US dollars.
| Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE, $bn) |
|---|---|---|---|---|---|---|
| 2021 | 81,288 | — | — | 4.42 | 1.56 | 36.2 |
| 2022 | 100,330 | +23.4% | — | 6.58 | 1.60 | 32.9 |
| 2023 | 58,496 | -41.7% | — | — | 1.64 | 61.5 |
| 2024 | 63,627 | +8.8% | 1.41 | 3.11 | 1.68 | 57.4 |
| 2025 | 62,579 | -1.6% | 1.36 | 3.22 | 1.72 | 61.6 |
For FY2025, cost of sales was $16.07bn, research and development $10.44bn, and amortisation of intangible assets $4.87bn; income from continuing operations before tax was $7.52bn. Operating cash flow was $11.7bn and capital expenditure $2.6bn, giving free cash flow of about $9.1bn. The quarterly table shows the most recent periods with the full-year 2025 total in bold (Q1 2025 EPS shown is derived from the reported full-year total less the other reported quarters).
| Quarter | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $14.45bn | $0.75 | $0.47 |
| Q4 2025 | $17.56bn | $0.66 | $(0.29) |
| Q3 2025 | $16.70bn | $0.87 | $0.62 |
| Q2 2025 | $14.70bn | $0.78 | $0.51 |
| Q1 2025 | $13.72bn | $0.91 | $0.52 |
| FY 2025 | $62.58bn | $3.22 | $1.36 |
6. Valuation
Raw metrics, May 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$149bn |
| Trailing P/E (GAAP) | ~19.2x (price ~$26.06 / FY2025 GAAP EPS $1.36) |
| P/E (forward) | ~9.0x (price ~$26.06 / ~$2.90 FY2026 adjusted EPS guidance midpoint) |
| P/S (TTM) | ~2.4x (market cap ~$149bn / revenue $62.58bn) |
| EV/EBITDA (TTM) | ~12x (EV ~$213bn / GAAP EBITDA ~$18bn; EBITDA ≈ pre-tax income $7.5bn + net interest ~$2.6bn + depreciation & intangible amortisation ~$7.6bn; GAAP EBITDA is depressed by ~$4.4bn of 2025 impairment and acquired-IPR&D charges) |
| P/FCF | ~16.4x (market cap ~$149bn / FCF ~$9.1bn; FCF = operating cash flow $11.7bn − capex $2.6bn per FY2025 cash flow statement) |
| Enterprise value | ~$213bn (market cap ~$149bn + total debt ~$64.8bn − cash & equivalents ~$1.1bn per FY2025 balance sheet) |
| 52-week high | $28.75 |
| 52-week low | $23.06 |
| Short interest (% of float) | ~1.99% (~113m shares short, May 2026) |
| Days to cover | ~2.85 |
7. Growth Drivers
Three engines are meant to offset the patent cliff. First, oncology: the Seagen-derived antibody-drug-conjugate portfolio, led by Padcev (up about 39% operationally in Q1 2026) plus Xtandi and Lorbrena, is taking share in bladder, prostate and lung cancers. Second, obesity and cardiometabolic disease: the ~$10bn Metsera acquisition added an ultra-long-acting incretin (PF-08653944) with potential monthly dosing, and Pfizer plans around ten pivotal obesity trials. Third, the existing growth base — the Vyndaqel cardiomyopathy family, Abrysvo and Prevnar vaccines, Nurtec and biosimilars — continues to expand.
Management has guided to roughly 20 key pivotal study starts in 2026 and expects new and acquired products to deliver double-digit growth, supported by a cost-realignment programme that funds reinvestment. Track upcoming catalysts on the ChartsView Economic Calendar.
8. Peer Comparison
| Peer | Market cap (2026) | Key metric |
|---|---|---|
| Johnson & Johnson (JNJ) | ~$565bn | Diversified pharma and medtech; broad oncology and immunology franchises |
| AbbVie (ABBV) | ~$390bn | Immunology (Skyrizi, Rinvoq), oncology, neuroscience and aesthetics |
| Merck & Co (MRK) | ~$302bn | Oncology leader via Keytruda; vaccines and animal health |
9. Insider Activity
No insider transactions of note (open-market purchases or sales) were identified in Pfizer's recent Form 4 filings for the period reviewed; activity was limited to routine equity-plan and deferred-compensation grants, including phantom stock units credited to directors. CEO and Chairman Albert Bourla continues to lead the company.
10. Key Risks
- Patent cliff / loss of exclusivity: Eliquis, Ibrance, Xtandi and Prevnar face exclusivity loss by 2028, putting an estimated $17–18bn of annual revenue at risk.
- Drug-pricing and IRA risk: Medicare price negotiation and broader pricing pressure reduce net revenue, with an Eliquis maximum fair price effective January 2026.
- Pipeline and clinical risk: Returns depend on R&D success, including obesity assets; the danuglipron discontinuation in 2025 shows the risk.
- M&A integration and dilution: The Metsera deal is expected to be dilutive through 2030 and adds integration risk on top of the Seagen acquisition.
- COVID revenue volatility: Comirnaty and Paxlovid revenues are unpredictable and weigh on comparisons.
- Litigation, macro and FX: Product-liability matters, currency moves and macro conditions can affect results.
11. Recent Developments
- 05 May 2026 — Q1 2026 results. Revenue rose 5% to $14.45bn; adjusted EPS was $0.75 (GAAP $0.47), beating expectations, and full-year 2026 guidance was reaffirmed.
- 19 May 2026 — Eliquis exclusivity. Eliquis lost European market exclusivity, beginning the erosion of one of Pfizer's largest products ahead of US generic entry.
- 03 Feb 2026 — full-year 2025 results. Revenue of $62.58bn (−2%); adjusted EPS $3.22 and GAAP EPS $1.36; FY2026 guidance reaffirmed.
- 13 Nov 2025 — Metsera acquisition won. Pfizer prevailed in a bidding war with Novo Nordisk, agreeing to acquire obesity specialist Metsera for up to about $10bn ($65.60 per share upfront plus contingent value rights).
12. Key Dates
- 04 Aug 2026 — expected second-quarter 2026 earnings release
- 05 Jun 2026 — approximate quarterly dividend payment date ($0.43 per share)
- 03 Feb 2027 — expected fourth-quarter and full-year 2026 results (based on prior-year timing)
Follow live pricing on ChartsView Live Charts and join the discussion in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Pfizer is a global biopharmaceutical company selling patent-protected medicines and vaccines across oncology, vaccines, internal medicine and rare disease. FY2025 revenue was $62.58bn (down 2%) with adjusted EPS of $3.22, and management reaffirmed FY2026 guidance of $59.5-62.5bn revenue and $2.80-3.00 adjusted EPS. The near-term driver is offsetting a looming patent cliff through oncology (Seagen/Padcev), an obesity platform from the ~$10bn Metsera deal, and cost discipline that funds a ~6.6% dividend.
What would confirm or break it. Confirmation would come from oncology and obesity pipeline progress and stable base-business revenue across upcoming filings. The thesis would break if the 2028 loss of exclusivity on Eliquis, Ibrance, Xtandi and Prevnar (an estimated $17-18bn of revenue) outpaced new launches, or if pipeline setbacks and dilutive M&A undermined the earnings and dividend profile.
Watchpoints
- ConfirmsQ2 2026 earnings (65 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Deep value and high yield:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Patent cliff / loss of exclusivity:" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 31 May 2026.